<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105946</url>
  </required_header>
  <id_info>
    <org_study_id>OFA in ENT</org_study_id>
    <nct_id>NCT04105946</nct_id>
  </id_info>
  <brief_title>Opioid Free Anesthesia in ENT Surgery</brief_title>
  <official_title>Opioid Free Anesthesia Versus Conventional Total Intravenous Anesthesia for ENT Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Thessaly</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid Free Anesthesia (OFA) - which has been applied mainly in bariatric surgery - has begun
      to receive more and more attention and to obtain fanatical supporters versus conventional
      anesthesia. The advantages of this type of anesthesia are mainly achieved by the action and
      effect of the various drugs that compose it.

      Functional Endoscopic Sinus Surgery is performed in cases where sinusitis or its
      complications are difficult to treat with medication. With special cameras and endoscopes,
      the narrow anatomical regions of the sinus can be depicted and precisely surgically
      approached. Usually surgery is conducted under general anesthesia. According to the
      literature, total intravenous anesthesia should be used for sinus surgery to achieve blood
      pressure control as well as controlled hypotension to prevent intraoperative bleeding. Most
      of the studies agree that the best type of anesthesia for this type of surgery is total
      intravenous anesthesia. When it comes to Opioid Free Anesthesia in FESS, there are not many
      studies, except of some studies that don't use solely Opioid Free Anesthesia but some of the
      drugs that consist it.

      Patients scheduled for elective Functional Endoscopic Sinus Surgery will be randomised in two
      groups. One receiving OFA and one receiving TIVA.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain management</measure>
    <time_frame>48 hours</time_frame>
    <description>Visual Analogue Scale score for pain after FESS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative bleeding in the surgical field</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Surgeon bleeding scale 0-3 for bleeding in the operative field</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>48 hours</time_frame>
    <description>Quality of recovery questionnaire for patient satisfaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Functional Endoscopic Sinus Surgery</condition>
  <arm_group>
    <arm_group_label>OFA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients undergoing FESS under opiod free anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients undergoing FESS under total intravenous anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>dexmedetomidine administration intraoperatively in combination with other drugs used in OFA</description>
    <arm_group_label>OFA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>remifentanil administration intraoperatively in combination with other drugs used in TIVA</description>
    <arm_group_label>TIVA Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 - 75 years old

          -  Elective FESS

        Exclusion Criteria:

          1. Patients &lt; 18 or &gt;75 years of age

          2. Patients who can't read of speak the Greek language

          3. Patients with psychiatric disorders

          4. Patients with atrioventricular block in ECG

          5. Patients with musculoskeletal disorders

          6. Patients with coronary artery disease

          7. Patients uncapable of giving informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Arnaoutoglou, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Thessaly</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Chatzioannou, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Thessaly</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dimitra Papaspirou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Larissa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Metaxia Bareka, MD, PhD</last_name>
    <phone>+306947845083</phone>
    <email>barekametaxia@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dimitra Papaspirou, MD</last_name>
    <phone>+306982004382</phone>
    <email>dimitra.papaspyrou@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univeristy of Thessaly</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Eleni Arnaoutoglou, MD, PhD</last_name>
      <phone>2413501370</phone>
      <email>earnaout@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dimitra Papaspirou</last_name>
      <phone>+306982004382</phone>
      <email>dimitra.papaspyrou@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Metaxia Bareka, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleni Arnaoutoglou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiannis Hajiioannou, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Athanasios Chalkias, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Thessaly</investigator_affiliation>
    <investigator_full_name>Elena Arnaoutoglou</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>FESS</keyword>
  <keyword>Opioid Free Anesthesia</keyword>
  <keyword>Opioid Consumption</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

